1. Home
  2. ACON vs XRTX Comparison

ACON vs XRTX Comparison

Compare ACON & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclarion Inc.

ACON

Aclarion Inc.

N/A

Current Price

$5.82

Market Cap

4.4M

Sector

Technology

ML Signal

N/A

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

N/A

Current Price

$0.61

Market Cap

4.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACON
XRTX
Founded
2008
2011
Country
United States
Canada
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.4M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ACON
XRTX
Price
$5.82
$0.61
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
66.3K
50.8K
Earning Date
11-12-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,483.00
N/A
Revenue This Year
$145.39
N/A
Revenue Next Year
$145.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.91
N/A
52 Week Low
$5.55
$0.52
52 Week High
$3,499.49
$1.79

Technical Indicators

Market Signals
Indicator
ACON
XRTX
Relative Strength Index (RSI) 42.43 43.19
Support Level $5.75 $0.58
Resistance Level $6.89 $0.62
Average True Range (ATR) 0.62 0.03
MACD 0.00 0.00
Stochastic Oscillator 7.14 12.35

Price Performance

Historical Comparison
ACON
XRTX

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: